Wenkui Ken Fang

USPTO Granted Patents = 44 (Patent Applications = 32)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 20 (Patent Applications = 22)

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 157(Granted Patents)

Company Filing History:

Years Active: 2001-2017

Loading Chart...

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9849113 - Methods of treating α adrenergic mediated conditions (2017-12-26),

2. 9623006 - Methods of treating α adrenergic mediated conditions (2017-04-18),

3. 9522150 - Alpha adrenergic receptor modulators (2016-12-20),

4. 9040532 - Alpha adrenergic receptor modulators (2015-05-26),

5. 9034910 - Methods of treating alpha adrenergic mediated conditions (2015-05-19),

6. 8993553 - Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2015-03-31),

7. 8957061 - Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2015-02-17),

8. 8906899 - Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-12-09),

9. 8871755 - Alkene azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-10-28),

10. 8846728 - Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-09-30),

11. 8809379 - Selective subtype alpha 2 adrenergic agents and methods for use thereof (2014-08-19),

12. 8754066 - Phenoxy derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-06-17),

13. 8735433 - Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-05-27),

14. 8735399 - Selective subtype alpha 2 adrenergic agents and methods for use thereof (2014-05-27),

15. 8729062 - Benzyl azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-05-20),

Title: Innovations by Wenkui Ken Fang: A Pioneer in α-Adrenergic Modulation

Introduction

Wenkui Ken Fang, based in Irvine, CA, is an accomplished inventor with a significant portfolio of 44 patents. His work primarily focuses on innovative methods for treating α-adrenergic mediated conditions, showcasing his commitment to advancing medical science and improving patient care.

Latest Patents

Among his latest patents are groundbreaking methods for treating α-adrenergic mediated conditions, which describe compounds and methods for addressing various diseases in subjects. These patents detail the administration of pharmaceutical compositions containing effective amounts of α-adrenergic modulators. Remarkably, Fang's inventions also encompass therapies that alleviate acute, neuropathic, and chronic pain, demonstrating his expansive reach into multifaceted health solutions.

Career Highlights

Throughout his career, Wenkui Ken Fang has been associated with prominent companies like Allergan, Inc. and Allergan Sales, Inc., where he played a pivotal role in research and development initiatives that have contributed to significant advancements in pharmaceuticals.

Collaborations

Fang's innovative work has also involved collaboration with talented professionals such as Ken Chow and Evelyn G. Corpuz. These collaborations highlight the importance of teamwork in achieving remarkable breakthroughs in the field of medicine and innovation.

Conclusion

Wenkui Ken Fang stands out as a leading inventor in the realm of α-adrenergic mediated treatments. With his extensive patent portfolio and collaborative approach, he continues to make invaluable contributions to the field of pharmacology, ultimately benefiting countless patients.

This text is generated by artificial intelligence and may not be accurate.